JP6112462B2 - 造血幹細胞及び前駆細胞のエクスビボ増殖のための方法 - Google Patents

造血幹細胞及び前駆細胞のエクスビボ増殖のための方法 Download PDF

Info

Publication number
JP6112462B2
JP6112462B2 JP2014531047A JP2014531047A JP6112462B2 JP 6112462 B2 JP6112462 B2 JP 6112462B2 JP 2014531047 A JP2014531047 A JP 2014531047A JP 2014531047 A JP2014531047 A JP 2014531047A JP 6112462 B2 JP6112462 B2 JP 6112462B2
Authority
JP
Japan
Prior art keywords
cells
hpc
ficolin
hsc
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014531047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527820A5 (enExample
JP2014527820A (ja
Inventor
メリンダ エル． タースキー，
メリンダ エル． タースキー，
マーク エー． カークランド，
マーク エー． カークランド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nohla Therapeutics Australia Pty Ltd
Original Assignee
Nohla Therapeutics Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011903899A external-priority patent/AU2011903899A0/en
Application filed by Nohla Therapeutics Australia Pty Ltd filed Critical Nohla Therapeutics Australia Pty Ltd
Publication of JP2014527820A publication Critical patent/JP2014527820A/ja
Publication of JP2014527820A5 publication Critical patent/JP2014527820A5/ja
Application granted granted Critical
Publication of JP6112462B2 publication Critical patent/JP6112462B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014531047A 2011-09-22 2012-09-21 造血幹細胞及び前駆細胞のエクスビボ増殖のための方法 Expired - Fee Related JP6112462B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011903899A AU2011903899A0 (en) 2011-09-22 Cell culture & expansion
AU2011903899 2011-09-22
PCT/AU2012/001135 WO2013040644A1 (en) 2011-09-22 2012-09-21 Method for the ex vivo expansion of hematopoietic stem and progenitor cells

Publications (3)

Publication Number Publication Date
JP2014527820A JP2014527820A (ja) 2014-10-23
JP2014527820A5 JP2014527820A5 (enExample) 2015-10-15
JP6112462B2 true JP6112462B2 (ja) 2017-04-12

Family

ID=47913674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531047A Expired - Fee Related JP6112462B2 (ja) 2011-09-22 2012-09-21 造血幹細胞及び前駆細胞のエクスビボ増殖のための方法

Country Status (10)

Country Link
US (1) US9518250B2 (enExample)
EP (1) EP2748309A4 (enExample)
JP (1) JP6112462B2 (enExample)
KR (1) KR20140063861A (enExample)
CN (1) CN104114694A (enExample)
AU (1) AU2012313347A1 (enExample)
CA (1) CA2885665A1 (enExample)
IL (1) IL231668A0 (enExample)
SG (1) SG11201400851PA (enExample)
WO (1) WO2013040644A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016178914A1 (en) * 2015-05-01 2016-11-10 Cesca Therapeutics, Inc. Intramuscular adaminstration of autologous bone marrw for treatment
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3331993A1 (en) * 2015-08-05 2018-06-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Use of dermatopontin for maintaining hematopoietic stem and/or progenitor cells in culture
US20200392533A1 (en) * 2017-04-11 2020-12-17 President And Fellows Of Harvard College In vivo gene editing of blood progenitors
CN110093313B (zh) * 2018-01-29 2023-04-14 华南生物医药研究院 促进造血干/祖细胞分化为红系细胞的诱导培养基及应用
EP3836974A4 (en) 2018-08-18 2022-06-15 President and Fellows of Harvard College IN SITU GENE EDIT
US20230212516A1 (en) * 2020-06-02 2023-07-06 Cornell University Methods for expanding hematopoietic stem cells
CN115861151B (zh) * 2021-09-23 2025-10-17 鸿海精密工业股份有限公司 细胞采收提醒方法及系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132017A1 (en) * 1996-12-09 2002-09-19 Moore Jeffrey G. Composition and method for preserving progenitor cells
US20050137126A1 (en) * 2003-04-09 2005-06-23 Natlmmune A/S Treatment of SARS in individuals
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
US20060205071A1 (en) 2003-07-17 2006-09-14 Gamida-Cell Ltd. Methods for ex-vivo expanding stem/progenitor cells
CN1297659C (zh) * 2004-02-11 2007-01-31 上海伯瑞生物技术发展有限公司 一种造血细胞灌注培养方法和装置
US7767453B2 (en) * 2004-10-20 2010-08-03 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
KR20090009186A (ko) * 2005-12-06 2009-01-22 디파트먼트 오브 바이오테크놀러지 사람의 조혈 줄기 세포 또는 선조 세포의 보존 방법
JP2008237136A (ja) 2007-03-28 2008-10-09 Foundation For Biomedical Research & Innovation ヒト造血細胞の培養方法
WO2008149129A1 (en) 2007-06-08 2008-12-11 Nova Thera Limited Cell expansion
CN101508975A (zh) * 2009-03-26 2009-08-19 大连理工大学 一种低氧条件下微囊化成骨细胞支持和调控造血干/祖细胞体外扩增的方法
WO2010142295A1 (en) * 2009-06-10 2010-12-16 Rigshospitalet Ficolin-3 assay
US20120169643A1 (en) 2009-09-09 2012-07-05 Sharp Kabushiki Kaisha Gesture determination device and method of same
CN102597223B (zh) * 2009-09-11 2017-05-10 宝生物工程株式会社 生产天然杀伤细胞的方法

Also Published As

Publication number Publication date
IL231668A0 (en) 2014-05-28
AU2012313347A1 (en) 2014-05-08
JP2014527820A (ja) 2014-10-23
US9518250B2 (en) 2016-12-13
CA2885665A1 (en) 2013-03-28
SG11201400851PA (en) 2014-04-28
EP2748309A4 (en) 2015-03-11
CN104114694A (zh) 2014-10-22
EP2748309A1 (en) 2014-07-02
KR20140063861A (ko) 2014-05-27
US20140286915A1 (en) 2014-09-25
WO2013040644A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
JP6112462B2 (ja) 造血幹細胞及び前駆細胞のエクスビボ増殖のための方法
Lam et al. Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice
JP7473984B2 (ja) 幹細胞移植のための方法および組成物
JP5283120B2 (ja) Ｅｓ細胞からの造血前駆細胞を内包する構造物、及び該構造物を用いた血球細胞の調製方法。
JP3810273B2 (ja) 幹細胞および前駆細胞の増殖と分化を制御する方法
US20250297222A1 (en) Xeno-free generation of tissue-specific progenitor cells
AU2016296920B2 (en) CD34+CD41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
Romanov et al. Human umbilical cord mesenchymal stromal cells support viability of umbilical cord blood hematopoietic stem cells but not the “stemness” of their progeny in co-culture
Deutsch et al. Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte‐progenitor cells from cord blood
Kim et al. Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model
KR20250006993A (ko) 방법
KR101149007B1 (ko) 생착능이 증가된 조혈줄기세포의 제조방법
Hasan Characterizing the Impact of the RNA Demethylase ALKBH5 on Hematopoietic Stem and Progenitor Cells
AU2003200124B2 (en) Method of Controlling Proliferation and Differentiation of Stem and Progenitor Cells
Kim Culture of Umbilical Cord-and Cord Blood-Derived Stem Cells
KR100999905B1 (ko) 생착능이 증가된 조혈줄기세포의 제조방법
WO2007148609A1 (ja) ＴＩＭＰ－３による造血幹細胞または造血前駆細胞のＥｘ ｖｉｖｏ／ｉｎ ｖｉｖｏ増殖
Carmen EFFECTS OF GROWTH FACTORS AND MEDIA ON THE EX VIVOEXPANSION OF CORD BLOOD HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR TRANSPLANTATION
Broun et al. 177Outcome of patients treated with high dose melphalan with or without TBI followed by CD34 selected stem cell rescue using the Baxter Isolex 3001
Sherman et al. 179Flow cytometric analysis of cellular differentiation arrest in myelodysplastic syndrome
La Russa et al. 178Engraftment and production of mesenchymal colony forming cells (M-CFC) in vitro
Yasuhisa et al. Derivation of functional mature neutrophils from human embryonic stem cells
Summers Identification, isolation and ex vivo expansion of haemopoietic progenitor and stem cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160719

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170303

R150 Certificate of patent or registration of utility model

Ref document number: 6112462

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees